Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Accounts Payables (2019 - 2025)

Historic Accounts Payables for Madrigal Pharmaceuticals (MDGL) over the last 13 years, with Q3 2025 value amounting to $44.9 million.

  • Madrigal Pharmaceuticals' Accounts Payables fell 222.99% to $44.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.9 million, marking a year-over-year decrease of 222.99%. This contributed to the annual value of $43.6 million for FY2024, which is 5548.3% up from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Accounts Payables of $44.9 million as of Q3 2025, which was down 222.99% from $38.0 million recorded in Q2 2025.
  • Madrigal Pharmaceuticals' 5-year Accounts Payables high stood at $46.0 million for Q3 2024, and its period low was $1.1 million during Q2 2021.
  • In the last 5 years, Madrigal Pharmaceuticals' Accounts Payables had a median value of $21.4 million in 2021 and averaged $22.8 million.
  • Data for Madrigal Pharmaceuticals' Accounts Payables shows a peak YoY increase of 200226.16% (in 2021) and a maximum YoY decrease of 7867.71% (in 2021) over the last 5 years.
  • Over the past 5 years, Madrigal Pharmaceuticals' Accounts Payables (Quarter) stood at $21.4 million in 2021, then grew by 11.46% to $23.8 million in 2022, then increased by 17.67% to $28.0 million in 2023, then surged by 55.48% to $43.6 million in 2024, then rose by 3.08% to $44.9 million in 2025.
  • Its Accounts Payables was $44.9 million in Q3 2025, compared to $38.0 million in Q2 2025 and $42.1 million in Q1 2025.